TACE与TARE治疗肝转移性乳腺癌的系统评价

IF 2.2 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Tomography Pub Date : 2025-07-12 DOI:10.3390/tomography11070081

Charalampos Lalenis, Alessandro Posa, Valentina Lancellotta, Marcello Lippi, Fabio Marazzi, Pierluigi Barbieri, Patrizia Cornacchione, Matthias Joachim Fischer, Luca Tagliaferri, Roberto Iezzi

{"title":"TACE与TARE治疗肝转移性乳腺癌的系统评价","authors":"Charalampos Lalenis, Alessandro Posa, Valentina Lancellotta, Marcello Lippi, Fabio Marazzi, Pierluigi Barbieri, Patrizia Cornacchione, Matthias Joachim Fischer, Luca Tagliaferri, Roberto Iezzi","doi":"10.3390/tomography11070081","DOIUrl":null,"url":null,"abstract":"Background/Objectives: Liver metastases are common among patients with breast cancer and have a poor prognosis if left untreated. The aim of this systematic review is to evaluate and compare chemoembolization (TACE) versus radioembolization (TARE) treatments in patients with breast cancer liver-dominant metastases in terms of overall survival (OS), local tumor control (LC), and toxicity. Methods: The S.P.I.D.E.R framework was used to address the clinical question. A systematic literature search using PubMed and Scopus was performed to identify full articles evaluating the efficacy of TACE and TARE in patients with liver metastases from breast cancer. Results: The literature search resulted in 10 articles for TACE, 13 articles for TARE and 1 for combined TACE/TARE, totaling 462 patients for the TACE group and 627 for the TARE group. The median LC was 68.7% for TACE and 78.9% for TARE. The median OS was 15.3 months for TACE and 11.9 for TARE. Progression at three months was 32.5% for TACE and 20.6% for TARE. Conclusions: The included studies were heterogeneous, varying widely in design, patient selection, and therapeutic protocols. Nonetheless, this systematic review suggests that locoregional therapies are effective in the treatment of liver metastases in patients with breast cancer and may improve tumor burden, alleviate symptoms and extend overall survival. The median LC of the liver metastases at three months was higher in the TARE group compared to TACE. However, the TARE group showed lower OS rates after treatment.","PeriodicalId":51330,"journal":{"name":"Tomography","volume":"11 7","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12300618/pdf/","citationCount":"0","resultStr":"{\"title\":\"TACE Versus TARE in the Treatment of Liver-Metastatic Breast Cancer: A Systematic Review.\",\"authors\":\"Charalampos Lalenis, Alessandro Posa, Valentina Lancellotta, Marcello Lippi, Fabio Marazzi, Pierluigi Barbieri, Patrizia Cornacchione, Matthias Joachim Fischer, Luca Tagliaferri, Roberto Iezzi\",\"doi\":\"10.3390/tomography11070081\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background/Objectives: Liver metastases are common among patients with breast cancer and have a poor prognosis if left untreated. The aim of this systematic review is to evaluate and compare chemoembolization (TACE) versus radioembolization (TARE) treatments in patients with breast cancer liver-dominant metastases in terms of overall survival (OS), local tumor control (LC), and toxicity. Methods: The S.P.I.D.E.R framework was used to address the clinical question. A systematic literature search using PubMed and Scopus was performed to identify full articles evaluating the efficacy of TACE and TARE in patients with liver metastases from breast cancer. Results: The literature search resulted in 10 articles for TACE, 13 articles for TARE and 1 for combined TACE/TARE, totaling 462 patients for the TACE group and 627 for the TARE group. The median LC was 68.7% for TACE and 78.9% for TARE. The median OS was 15.3 months for TACE and 11.9 for TARE. Progression at three months was 32.5% for TACE and 20.6% for TARE. Conclusions: The included studies were heterogeneous, varying widely in design, patient selection, and therapeutic protocols. Nonetheless, this systematic review suggests that locoregional therapies are effective in the treatment of liver metastases in patients with breast cancer and may improve tumor burden, alleviate symptoms and extend overall survival. The median LC of the liver metastases at three months was higher in the TARE group compared to TACE. However, the TARE group showed lower OS rates after treatment.\",\"PeriodicalId\":51330,\"journal\":{\"name\":\"Tomography\",\"volume\":\"11 7\",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-07-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12300618/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tomography\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/tomography11070081\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tomography","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/tomography11070081","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

摘要

背景/目的：肝转移在乳腺癌患者中很常见，如果不及时治疗，预后很差。本系统综述的目的是评估和比较化疗栓塞（TACE）与放射栓塞（TARE）治疗乳腺癌肝脏转移患者的总生存期（OS）、局部肿瘤控制（LC）和毒性。方法：采用spi.d.e.r框架解决临床问题。使用PubMed和Scopus进行系统的文献检索，以确定评估TACE和TARE在乳腺癌肝转移患者中的疗效的完整文章。结果：检索到TACE文献10篇，TARE文献13篇，TACE/TARE联合文献1篇，TACE组462例，TARE组627例。TACE的中位LC为68.7%，TARE为78.9%。TACE的中位OS为15.3个月，TARE为11.9个月。3个月时TACE和TARE的进展率分别为32.5%和20.6%。结论：纳入的研究是异质性的，在设计、患者选择和治疗方案上差异很大。尽管如此，本系统综述表明，局部治疗在治疗乳腺癌肝转移患者中是有效的，并且可以改善肿瘤负担，缓解症状并延长总生存期。TARE组3个月时肝转移的中位LC高于TACE组。然而，TARE组在治疗后的OS率较低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

TACE Versus TARE in the Treatment of Liver-Metastatic Breast Cancer: A Systematic Review.

查看原文本刊更多论文

TACE Versus TARE in the Treatment of Liver-Metastatic Breast Cancer: A Systematic Review.

Background/Objectives: Liver metastases are common among patients with breast cancer and have a poor prognosis if left untreated. The aim of this systematic review is to evaluate and compare chemoembolization (TACE) versus radioembolization (TARE) treatments in patients with breast cancer liver-dominant metastases in terms of overall survival (OS), local tumor control (LC), and toxicity. Methods: The S.P.I.D.E.R framework was used to address the clinical question. A systematic literature search using PubMed and Scopus was performed to identify full articles evaluating the efficacy of TACE and TARE in patients with liver metastases from breast cancer. Results: The literature search resulted in 10 articles for TACE, 13 articles for TARE and 1 for combined TACE/TARE, totaling 462 patients for the TACE group and 627 for the TARE group. The median LC was 68.7% for TACE and 78.9% for TARE. The median OS was 15.3 months for TACE and 11.9 for TARE. Progression at three months was 32.5% for TACE and 20.6% for TARE. Conclusions: The included studies were heterogeneous, varying widely in design, patient selection, and therapeutic protocols. Nonetheless, this systematic review suggests that locoregional therapies are effective in the treatment of liver metastases in patients with breast cancer and may improve tumor burden, alleviate symptoms and extend overall survival. The median LC of the liver metastases at three months was higher in the TARE group compared to TACE. However, the TARE group showed lower OS rates after treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Tomography Medicine-Radiology, Nuclear Medicine and Imaging

CiteScore

2.70

自引率

10.50%

发文量

222

期刊介绍： TomographyTM publishes basic (technical and pre-clinical) and clinical scientific articles which involve the advancement of imaging technologies. Tomography encompasses studies that use single or multiple imaging modalities including for example CT, US, PET, SPECT, MR and hyperpolarization technologies, as well as optical modalities (i.e. bioluminescence, photoacoustic, endomicroscopy, fiber optic imaging and optical computed tomography) in basic sciences, engineering, preclinical and clinical medicine. Tomography also welcomes studies involving exploration and refinement of contrast mechanisms and image-derived metrics within and across modalities toward the development of novel imaging probes for image-based feedback and intervention. The use of imaging in biology and medicine provides unparalleled opportunities to noninvasively interrogate tissues to obtain real-time dynamic and quantitative information required for diagnosis and response to interventions and to follow evolving pathological conditions. As multi-modal studies and the complexities of imaging technologies themselves are ever increasing to provide advanced information to scientists and clinicians. Tomography provides a unique publication venue allowing investigators the opportunity to more precisely communicate integrated findings related to the diverse and heterogeneous features associated with underlying anatomical, physiological, functional, metabolic and molecular genetic activities of normal and diseased tissue. Thus Tomography publishes peer-reviewed articles which involve the broad use of imaging of any tissue and disease type including both preclinical and clinical investigations. In addition, hardware/software along with chemical and molecular probe advances are welcome as they are deemed to significantly contribute towards the long-term goal of improving the overall impact of imaging on scientific and clinical discovery.